Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Accuracy of healthcare systems data for identifying cardiovascular outcomes after stroke due to intracerebral haemorrhage in the United Kingdom.

Hosking A. et al, (2024), Trials, 25

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.

Judge PK. et al, (2024), Nephrol Dial Transplant

Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.

EMPA-KIDNEY Collaborative Group None. et al, (2024), N Engl J Med

Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial

Mayne K. et al, (2024), Nephrology Dialysis Transplantation

Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial

Mayne K. and HERRINGTON W., (2024), American Society of Nephrology. Clinical Journal

Thromboxane biosynthesis and future events in diabetes: the ASCEND trial.

Petrucci G. et al, (2024), Eur Heart J, 45, 1355 - 1367

Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study

MIHAYLOVA B. et al, (2024), The Lancet Regional Health - Europe

Thromboxane biosynthesis and risk of future events in diabetes mellitus: A sub-study of the ASCEND trial.

PARISH S. et al, (2023), European Heart Journal

Effects of Empagliflozin on Fluid Overload, Weight and Blood Pressure in Chronic Kidney Disease

Mayne K. et al, (2023), Journal of the American Society of Nephrology

Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence.

Baigent C. and Sádaba R., (2023), Eur Heart J

Revascularization of low-surgical risk patients with disease of the left main coronary artery: a fresh look at the evidence.

Baigent C. and Sádaba R., (2023), Eur J Cardiothorac Surg, 64

Empagliflozin in Patients with Chronic Kidney Disease. Reply.

Herrington WG. et al, (2023), N Engl J Med, 388, 2301 - 2302

Impact of outcome adjudication in kidney disease trials: observations from the Study of Heart and Renal Protection (SHARP)

HERRINGTON W. et al, (2023), Kidney International Reports

Interference of urinary albumin-to-creatinine ratio measurement by glycosuria: clinical implications when using SGLT-2 inhibitors.

Chapman D. et al, (2023), Kidney Int

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Humbert M. et al, (2023), European Respiratory Journal, 61

Prediction models for individual-level healthcare costs associated with cardiovascular events in the UK

Zhou J. et al, (2022), PharmacoEconomics

Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study

HERRINGTON W. et al, (2022), Clinical Journal of the American Society of Nephrology

Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses.

Gaziano L. et al, (2022), Circulation

Empagliflozin in Patients with Chronic Kidney Disease

HERRINGTON W. et al, (2022), New England Journal of Medicine

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials

HERRINGTON W. et al, (2022), The Lancet

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?